Management tracks: Inflazome, Clementia
Two weeks after raising €40 million ($45.7 million) in a series B round in preparation for its first clinical trials which are slated for next year, Inflazome Ltd. (Dublin, Ireland) hired Thomas Jung as its first CMO. Jung was at Novartis AG (NYSE:NVS; SIX:NOVN) for 13 years prior to his departure in 2011 as the company's European translational medicine head. He's since held CMO and chief development officer positions at Delenex Therapeutics AG and Auris Medical Holding AG (NASDAQ:EARS), respectively. Cell Medica Ltd. (London, U.K.) acquired Delenex in 2016 (see "Inflazome to Bring Inflammasome Inhibitors to Clinic with €40 Million Series B").
Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) said Chief Commercial Officer Eric Grinstead will leave the rare disease company. The news comes a month after Clementia said it will submit an NDA to FDA in 2H19 for fibrodysplasia ossificans progressiva (FOP) therapy palovarotene. If approved, it would be the first-ever commercialized therapy for the rare bone disease and Clementia's first marketed product...